SULPHONAMIDES MARKET 2022-2030

Description

Market Overview

The Sulphonamides market studied is anticipated to grow with a CAGR of nearly 4.1%, during the forecast period.

COVID-19 pandemic had a substantial impact on patients with any underlying diseases, antibiotics helped the patient to combat its effect. However, many antibiotics were initially used to treat COVID-19 and are widely prescribed and studied as the COVID-19 remedy. In wake of the COVID-19 outbreak, antibiotics are improving public health along with decreasing the potential of other infectious exposures.

According to the report published by the Centers for Disease Control and Prevention titled 'COVID-19 U.S. impact on antimicrobial resistance' in 2022 from March 2020 to October 2020, almost 80% of patients hospitalized with COVID-19 received an antibiotic. Antibiotic use was lower overall as of August 2021 compared to 2019 but increased for some antibiotics like azithromycin and ceftriaxone.

As per an article published in Science Direct titled ‘Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2’ in January 2021 stated that a novel class of cyclic sulfonamide derivatives as a promising new template for SARS-CoV-2 inhibitors using structural activity relationship optimization, viral inhibitory assays, cytotoxicity assays, and pharmacokinetic studies. Thus, the COVID-19 outbreak had a negative impact on sulphonamides market. However, the sulphonamides market is expected to grow due to the significant increase in the use of antibiotics globally.

Certain factors that are driving the market growth include increasing prevalence of chronic diseases worldwide and growing R&D activities in pharmaceutical companies. As per an article published in Wiley online Library titled ‘Prevalence of most common skin diseases in Europe: a population-based study’ in March 2022, estimated more than 94 million Europeans complain of uncomfortable skin sensations like itch, burning, or dryness. The most frequent conditions were fungal skin infections (8.9%), acne (5.4%), and atopic dermatitis or eczema (5.5%). Alopecia, acne, eczema, and rosacea were more common in women, whereas men were more likely to suffer from psoriasis and sexually transmitted infections. Similarlly, the diverse range of diseases skin infections, gastro intestinal tract (GIT) Infection, urinary tract infection, respiratory tract infection has a high prevalence, globally. Thus, the increasing prevalence of a diverse range of infections among all age groups and its burden, globally, drives the demand for the market. 

There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics and combinatorial chemistry for better drug candidate identification. Drug discovery has evolved significantly with emerging technologies, helping the process to become more refined, accurate, and less time-consuming. Due to automation, multi-detector readers, imaging hardware and software, high-throughput screening is one of the most widely used drug discovery technologies.

By Route of Administration

  • Oral
  • Topical

By Application

  • Skin Infections
  • Gastro Intestinal Tract (GIT) Infection
  • Urinary Tract Infection (UTI)
  • Respiratory Tract Infection (RTI)
  • Others

Key Market Trends

Urinary tract infection is Expected to Witness Significant Growth Over the Forecast Period

Urinary tract infection (UTI) affects the urinary tract. It is one of the most common bacterial infections, and it is more common in women, as compared to men. UTI is considered one of the most frequent causes of morbidity and mortality, globally. The prevalence of uncomplicated UTI is significantly higher, as compared to recurring complicated UTI.

According to the article published in Microbiology Society titled ‘Prevalence and resistance pattern of uropathogens from community settings of different regions: an experience from India’ in February 2022 stated that 10.1 % of urine samples were positive for bacteria with significant bacteriuria. Females were predominantly affected. History of recent episodes of UTI was observed as the commonest risk factor followed by diabetes mellitus. Among the commonly used oral antibiotics for the gram-negative bacilli (GNB), the highest resistance was observed against beta-lactams, first- and second-generation cephalosporins, fluoroquinolones and co-trimoxazole. Higher prevalence of UTI, will increase the usage of sulphonamide, and will boost the market in forecasted year.

According to another article published in National Library of Medicine titled 'Symptoms, risk factors, diagnosis and treatment of urinary tract infections' in November 2020 that diagnostic failures in case of bacterial infections are the main contributing factor in improper use of antibiotics, delay in treatment and low survival rate in septic conditions. So, early diagnosis and appropriate therapy with antibiotics are the most significant requirements for preventing complicated UTI conditions such as urosepsis. Early diagnosis will not only boost the sulphonamides market, but will also provide efficient and early treatment.

Major players are also focusing on the development of diagnostics tools for urinary tract infection. For instance, In January 2020, Sysmex Corporation has reached an agreement to invest in Astrego Diagnostics AB. Through this investment, Sysmex aims to help commercialize a rapid drug susceptibility test that Astrego is developing for urinary tract infections.

Additionally, substantial availability of various sulfonamide drug formulations at reasonable price, the prevalence of complicated UTI is expected to increase in the future, owing to the rise in drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe sulphonamides to treat UTI cases.

North America Dominates the Global Sulphonamides Market

North America is expected to dominate the market owing to factors such as growing R&D activities in the medical sciences, availability of technologically advanced products, rising antibiotics use and the growing aging population.

For instance, according to the October 2021 update of the Centers for Disease Control and Prevention (CDC), in 2020, approximately 7,174 new cases of tuberculosis (TB) were reported in the United States. As per the same source, the prevalence of TB was reported to be highest among Hispanic or Latino persons, who accounted for about 30% of the total TB cases reported in the country. Thus, the presence of new TB cases in the country is expected to drive the demand for sulphonamides in the region which is likely to drive the growth of the studied market in the region.

The other major factor that will complement the demand for antibiotics in North America is the growing geriatric population who are more prone to infections. For instance, according to an article published United States Department of Health and Human Services titled 'Projected Future Growth of Older Population' in April 2022, it is projected to reach 80.8 million by 2040 and 94.7 million by 2060.

Moreover, in North America, the United States is expected to hold a major share in the antibiotics market during the forecast period due to the high prevalence and incidence of infectious diseases and the wide availability of antibiotics. According to the November 2021 article of the Centers for Disease Control and Prevention, the common cold affects millions of people in the United States each year. Adults have 2-3 colds every year on average, and children get even more. Thus, due to the high burden of bacterial infectious diseases in the country, the United States is expected to hold a major share in the sulphonamides market in the North American region.

Competitive Landscape

The global Sulphonamides market is fragmented and consists of a several major players. Companies like AA Pharma Inc., Abbott Laboratories, Akorn Operating Company LLC, GlaxoSmithKline plc, Lexine Technochem Pvt. Ltd., Mylan Pharmaceuticals, Amneal Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc., among others, hold the substantial market share in the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with less prices.

Recent Development

  • In July 2022, GSK plc announced it has completed the acquisition of Sierra Oncology, Inc. (Sierra Oncology), a California-based biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer.
  • In March 2021, Teva Pharmaceuticals USA, Inc. announced the launch of the first available generic version of Azopt (Brinzolamide ophthalmic suspension 1% is a sulfonamide), approved by the United States Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma.

TABLE OF CONTENT

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Chronic Diseases Worldwide

      2. 4.2.2 Growing R&D Activities in Pharmaceutical Companies

    3. 4.3 Market Restraints

      1. 4.3.1 Increasing Side Effects associated with the Use of Sulfa Drugs

      2. 4.3.2 Availability of Substitute Drugs

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Route of Administration

      1. 5.1.1 Oral

      2. 5.1.2 Topical

    2. 5.2 By Application

      1. 5.2.1 Skin Infections

      2. 5.2.2 Gastro Intestinal Tract (GIT) Infection

      3. 5.2.3 Urinary Tract Infection (UTI)

      4. 5.2.4 Respiratory Tract Infection (RTI)

      5. 5.2.5 Others

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

      1. 6.1 Company Profiles

        1. 6.1.1 AA Pharma Inc.

        2. 6.1.2 Abbott Laboratories

        3. 6.1.3 F. Hoffmann-La Roche Ltd

        4. 6.1.4 GlaxoSmithKline plc

        5. 6.1.5 Lexine Technochem Pvt. Ltd.

        6. 6.1.6 Mylan Pharmaceuticals

        7. 6.1.7 Pfizer Inc.

        8. 6.1.8 Teva Pharmaceuticals USA, Inc.

        9. 6.1.9

        10. 6.1.10

        11. 6.1.11

    *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Delivery Format : EXCEL/Data Pack

Choose License Type

Checkout Inquiry Sample